Supporting local vaccine and immunotherapy production and self-reliance.

Our immune-enhancing platforms use standard emulsion manufacturing technology and innovative and efficient manufacturing techniques that can be transferred to enable local production in low-and-middle income countries around the world.

  • Our technology transfer and training in adjuvant manufacturing techniques enables self-reliance, even in low-resource areas, and fosters local production and expanded availability of vaccines and immunotherapies.
  • Our NLC are produced with standard emulsification equipment and techniques to support global accessibility, including by eliminating the significant logistical difficulties that encumber production of Lipid Nanoparticles (LNPs) used with current RNA vaccines.